

Drugs and Therapeutics (D & T) Committee

Meeting Results October 5, 2023

Drug Name	Review Type	Committee Recommendation	Preferred Status – Final Determination
Dificid	New Drug Initial Review	Preferred	Preferred
Austedo XR	New Drug Initial Review	Preferred with PA	Preferred with PA
Uzedly	New Drug Initial Review	Preferred with PA	Preferred with PA
Abilify Asimtufi	New Drug Initial Review	Preferred with PA	Preferred with PA
Prevymis	New Drug Initial Review	Preferred with PA	Preferred with PA
Elevidys	New Drug Initial Review	Non-Preferred	Non-Preferred
Vyjuvek	New Drug Initial Review	Tabled for Discussion at the January meeting	Tabled
Tadliq	New Drug Initial Review	Non-Preferred	Non-Preferred
Perseris	PDL Appeal	Preferred with PA	Preferred with PA
Rinvoq	PDL Appeal	Non-Preferred	Non-Preferred
Skyrizi	PDL Appeal	Non-Preferred	Non-Preferred

Anti-Obesity Class Review

The D&T Advisory Board recommended adding the Anti-Obesity class to the PDL. The Department will add the class as soon as possible and will review the class for drug status placement at a later date.
--

The minutes reflecting these D&T Advisory Board actions are contained in draft minutes, yet to be approved at the next board meeting. Following that, this post will be updated only if there are amendments to those minutes.
